Register or Login
All
  • All
  • Uniprot Id
  • Catalog #
  • Peptide Sequence
>   home   >   Products   >   Primary Antibodies   >   Cancer   >   MAGEA4 Antibody   

MAGEA4 Antibody

     
  • IHC - MAGEA4 Antibody ASC11929
    Immunohistochemistry of NOX2 in rat brain tissue cells with NOX2 antibody at 2 µg/ml.
  • WB - MAGEA4 Antibody ASC11929
    Western blot analysis of TRIM30 in mouse heart tissue lysate with TRIM30 antibody at (A) 1 and (B) 2 µg/mL.
  • SPECIFICATION
  • CITATIONS
  • PROTOCOLS
  • BACKGROUND
Product Information
Application
  • Applications Legend:
  • WB=Western Blot
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin-embedded Sections)
  • IHC-F=Immunohistochemistry (Frozen Sections)
  • IF=Immunofluorescence
  • FC=Flow Cytopmetry
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • E=ELISA
  • IP=Immunoprecipitation
  • DB=Dot Blot
  • CHIP=Chromatin Immunoprecipitation
  • FA=Fluorescence Assay
  • IEM=Immunoelectronmicroscopy
  • EIA=Enzyme Immunoassay
WB, IHC-P, IF, E
Primary Accession P43358
Other Accession NP_001011550, 4103
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Isotype IgG
Calculated MW Predicted: 35 kDa; Observed: 45 kDa
Application Notes MAGEA4 antibody can be used for detection of MAGEA4 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Additional Information
Gene ID 4103
Target/Specificity MAGEA4 antibody was raised against a 16 amino acid peptide near the amino terminus of human MAGEA4.

The immunogen is located within the first 50 amino acids of MAGEA4.
Reconstitution & Storage MAGEA4 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.
PrecautionsMAGEA4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name MAGEA4
Synonyms MAGE4
Function Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.
Tissue Location Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta EMBL; U10687; AAA68871.1; -; Genomic_DNA EMBL; U10688; AAA68872.1; -; Genomic_DNA EMBL; U10340; AAA19007.1; -; mRNA EMBL; D32075; BAA06841.1; -; mRNA EMBL; D32077; BAA06843.1; -; mRNA EMBL; AF274855; -; NOT_ANNOTATED_CDS; Genomic_DNA EMBL; BC017723; AAH17723.1; -; mRNA CCDS; CCDS14702.1; - PIR; I38661; I38661 RefSeq; NP_001011548.1; NM_001011548.1 RefSeq; NP_001011549.1; NM_001011549.1 RefSeq; NP_001011550.1; NM_001011550.1 RefSeq; NP_002353.3; NM_002362.4 RefSeq; XP_005274735.1; XM_005274678.3 RefSeq; XP_005274736.1; XM_005274679.3 UniGene; Hs.37107; - PDB; 1I4F; X-ray; 1.40 A; C=230-239 PDB; 2WA0; X-ray; 2.30 A; A=101-317 PDBsum; 1I4F; - PDBsum; 2WA0; - ProteinModelPortal; P43358; - SMR; P43358; - BioGrid; 110277; 33 IntAct; P43358; 21 MINT; P43358; - STRING; 9606.ENSP00000276344; - iPTMnet; P43358; - PhosphoSitePlus; P43358; - BioMuta; MAGEA4; - DMDM; 322510046; - EPD; P43358; - MaxQB; P43358; - PaxDb; P43358; - PeptideAtlas; P43358; - PRIDE; P43358; - ProteomicsDB; 55620; - DNASU; 4103; - Ensembl; ENST00000276344; ENSP00000276344; ENSG00000147381 Ensembl; ENST00000360243; ENSP00000353379; ENSG00000147381 Ensembl; ENST00000370335; ENSP00000359360; ENSG00000147381 Ensembl; ENST00000370340; ENSP00000359365; ENSG00000147381 Ensembl; ENST00000393920; ENSP00000377497; ENSG00000147381 Ensembl; ENST00000393921; ENSP00000377498; ENSG00000147381 GeneID; 4103; - KEGG; hsa:4103; - UCSC; uc004ffa.3; human CTD; 4103; - DisGeNET; 4103; - EuPathDB; HostDB:ENSG00000147381.11; - GeneCards; MAGEA4; - HGNC; HGNC:6802; MAGEA4 HPA; CAB040535; - HPA; HPA021942; - MIM; 300175; gene neXtProt; NX_P43358; - OpenTargets; ENSG00000147381; - PharmGKB; PA30548; - eggNOG; KOG4562; Eukaryota eggNOG; ENOG4111S70; LUCA GeneTree; ENSGT00760000118824; - HOGENOM; HOG000231161; - HOVERGEN; HBG006315; - InParanoid; P43358; - OMA; WEELGVM; - OrthoDB; EOG091G0TJ0; - PhylomeDB; P43358; - TreeFam; TF328505; - ChiTaRS; MAGEA4; human EvolutionaryTrace; P43358; - GeneWiki; MAGEA4; - GenomeRNAi; 4103; - PRO; PR:P43358; - Proteomes; UP000005640; Chromosome X Bgee; ENSG00000147381; - CleanEx; HS_MAGEA4; - ExpressionAtlas; P43358; baseline and differential Genevisible; P43358; HS InterPro; IPR037445; MAGE InterPro; IPR021072; MAGE_N InterPro; IPR030098; MAGEA4/MAGEA5 InterPro; IPR002190; MHD_dom PANTHER; PTHR11736; PTHR11736; 1 PANTHER; PTHR11736:SF48; PTHR11736:SF48; 1 Pfam; PF01454; MAGE; 1 Pfam; PF12440; MAGE_N; 1 SMART; SM01373; MAGE; 1 SMART; SM01392; MAGE_N; 1 PROSITE; PS50838; MAGE; 1 1: Evidence at protein level; 3D-structure; Complete proteome; Polymorphism; Reference proteome; Tumor antigen CHAIN 1 317 Melanoma-associated antigen 4 /FTId=PRO_0000156704 DOMAIN 110 309 MAGE. {ECO:0000255|PROSITE- ProRule:PRU00127} COMPBIAS 41 44 Poly-Ser VARIANT 137 137 L -> Q. /FTId=VAR_076262 VARIANT 153 153 G -> D (in a breast cancer sample; somatic mutation) /FTId=VAR_036582 VARIANT 173 173 A -> T (in dbSNP:rs1047251) /FTId=VAR_004284 VARIANT 230 230 G -> E (in dbSNP:rs773875619) /FTId=VAR_078319 CONFLICT 3 3 S -> L (in Ref. 3; BAA06841) CONFLICT 48 48 P -> L (in Ref. 3; BAA06841) CONFLICT 53 53 E -> K (in Ref. 3; BAA06841) CONFLICT 61 61 G -> D (in Ref. 3; BAA06841) CONFLICT 95 96 GP -> EA (in Ref. 3; BAA06841) CONFLICT 307 307 E -> Q (in Ref. 2; AAA19007) HELIX 102 126 {ECO:0000244|PDB:2WA0} HELIX 133 139 {ECO:0000244|PDB:2WA0} HELIX 145 147 {ECO:0000244|PDB:2WA0} HELIX 148 163 {ECO:0000244|PDB:2WA0} STRAND 165 169 {ECO:0000244|PDB:2WA0} STRAND 176 181 {ECO:0000244|PDB:2WA0} HELIX 182 184 {ECO:0000244|PDB:2WA0} HELIX 200 213 {ECO:0000244|PDB:2WA0} HELIX 219 228 {ECO:0000244|PDB:2WA0} TURN 238 240 {ECO:0000244|PDB:2WA0} HELIX 243 248 {ECO:0000244|PDB:2WA0} HELIX 250 253 {ECO:0000244|PDB:2WA0} STRAND 256 260 {ECO:0000244|PDB:2WA0} STRAND 271 274 {ECO:0000244|PDB:2WA0} HELIX 276 281 {ECO:0000244|PDB:2WA0} HELIX 284 295 {ECO:0000244|PDB:2WA0} HELIX 305 309 {ECO:0000244|PDB:2WA0} SEQUENCE 317 AA; 34899 MW; C6AA2EE306963E7D CRC64; MSSEQKSQHC KPEEGVEAQE EALGLVGAQA PTTEEQEAAV SSSSPLVPGT LEEVPAAESA GPPQSPQGAS ALPTTISFTC WRQPNEGSSS QEEEGPSTSP DAESLFREAL SNKVDELAHF LLRKYRAKEL VTKAEMLERV IKNYKRCFPV IFGKASESLK MIFGIDVKEV DPASNTYTLV TCLGLSYDGL LGNNQIFPKT GLLIIVLGTI AMEGDSASEE EIWEELGVMG VYDGREHTVY GEPRKLLTQD WVQENYLEYR QVPGSNPARY EFLWGPRALA ETSYVKVLEH VVRVNARVRI AYPSLREAAL LEEEEGV
Research Areas
Citations (0)

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.

Submit your citation using an Abgent antibody to
info@abgent.com, and receive a free "I Love Antibodies" mug.

Background

MAGEA4 is a member of the melanoma-associated antigen family that consists of a number of antigens recognized by cytotoxic T lymphocytes (1). MAGEA4 may serve as a target for antitumoral vaccination and may play a role in embryonal development and tumor transformation or aspects of tumor progression. It is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma and have been implicated in some hereditary disorders, such as dyskeratosis congenital (2-4).

References

Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin. Cancer Res. 2011; 17:4267-76.
Bhan S, Chuang A, Negi SS, et al. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol. Rep. 2012; 28:1498-502.
Saito T, Wada H, Yamasaki M, et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, epub. 2014; S0264-410X(14)01217-1.
Zhang QM, He SJ, Shen N, et al. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int. J. Clin. Exp. Pathol. 2014; 7:3918-27.

FeedBack
Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

$ 330.00
Cat# ASC11929
Size:
Quantity:
Availability: 5-7days
Bulk Size
Seasonal Special on Bulk Order
Request Quote Here

Ordering Information

United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
Abgent, Inc.
(888) 735-7227 / (858) 622-0099
(858) 622-0609
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900

Shipping Information

Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
“Crown Flash”  50 % off on 2,500+ Crown Antibodies. PromoCode:<span class=text-red> FLASH50
Terms & Conditions